Header

UZH-Logo

Maintenance Infos

Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy?


Diem, Stefan; Keller, Fabienne; Rüesch, Reinhard; Maillard, Samia A; Speiser, Daniel E; Dummer, Reinhard; Siano, Marco; Urner-Bloch, Ursula; Goldinger, Simone M; Flatz, Lukas (2016). Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy? Journal of Immunotherapy, 39(9):379-382.

Abstract

Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis may serve as a surrogate marker for a tumor response to therapy with pembrolizumab.

Abstract

Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis may serve as a surrogate marker for a tumor response to therapy with pembrolizumab.

Statistics

Citations

3 citations in Web of Science®
3 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

3 downloads since deposited on 07 Nov 2016
1 download since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2016
Deposited On:07 Nov 2016 08:28
Last Modified:01 Nov 2017 01:01
Publisher:Lippincott Williams & Wilkins
ISSN:1524-9557
Publisher DOI:https://doi.org/10.1097/CJI.0000000000000143
PubMed ID:27662340

Download

Download PDF  'Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy?'.
Preview
Content: Published Version
Filetype: PDF
Size: 332kB
View at publisher